Sign up to save your podcasts
Or
Share Applying Clinical Trial Data on Newer CHCs into Real-World Patient Care
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Applying Clinical Trial Data on Newer CHCs into Real-World Patient Care
CME credits: 0.25
Valid until: 31-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/applying-clinical-trial-data-on-newer-chcs-into-real-world-patient-care/12689/
The effort to reduce the estrogen concentration in combination oral contraceptives (COCs) and strike the right balance between efficacy and safety appears to be never-ending. However, a recently FDA-approved estetrol/drospirenone COC formulation offers some unique properties not seen in current COC formulations. Join us as Dr. Jeffrey Jensen and Dr. Lee Shulman discuss if this estetrol/drospirenone COC formulation will allow physicians to better address these efficacy and safety issues.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 31-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/applying-clinical-trial-data-on-newer-chcs-into-real-world-patient-care/12689/
The effort to reduce the estrogen concentration in combination oral contraceptives (COCs) and strike the right balance between efficacy and safety appears to be never-ending. However, a recently FDA-approved estetrol/drospirenone COC formulation offers some unique properties not seen in current COC formulations. Join us as Dr. Jeffrey Jensen and Dr. Lee Shulman discuss if this estetrol/drospirenone COC formulation will allow physicians to better address these efficacy and safety issues.